LABORATORY REPORT

Name	: **JENITHA PALIN**	File. No.	: **AAL02-388563**
DOB/Gender	: **28-09-1997 (27 Yrs 1 Month 17 Days/Female)**	Referral Doctor	: **Dr. Mohammed M Hamed Hashish**
Lab No.	: **22242960331**	Referral Clinic	: **Citicare Medical Center LLC**
Request Date	: **22-10-2024 19:39:05**	Clinic File No	: **42924**
Insurance	: **NEXTCARE**		

HORMONES/ENDOCRINE/TUMOR MARKERS

Test Name	Result	Units	Ref. Range	Method
FSH (Follicle Stimulating Hormone)	6.94	mIU/mL	Normal menstruating females: Follicular phase: 3.5-12.5 Ovulation Phase: 4.7-21.5 Luteal phase: 1.7-7.7 Post menopausal : 25.8-134.8	ECLIA

Conversion Formula: (Concentration in mIU/mL) x (1.0) = IU/L.

Determination of the FSH concentration is used in the elucidation of dysfunctions within the hypothalamus pituitary gonads system. The determination of FSH in conjunction with LH is utilized for the following indications: congenital diseases with chromosome aberrations, polycystic ovaries (PCO), amenorrhea (causes), and menopausal syndrome.

Depressed gonadotropin levels in men occur in azoospermia. Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Please note Reference Range Reviewed w.ef 09/01/24 .

Test Name	Result	Units	Ref. Range	Method
Luteinising Hormone (LH)	18.80	mIU/mL	Normal menstruating females: Follicular phase: 2.4-12.6 Ovulation Phase: 14.0-95.6 Luteal phase: 1.0-11.4 Post menopausal : 7.7-58.5	ECLIA

Conversion Formula: (Concentration in mIU/mL) x (1) = IU/L. Determination of the LH concentration is used in the elucidation of dysfunctions within the hypothalamuspituitarygonads system. The determination of LH in conjunction with FSH is utilized for the following indications: congenital diseases with chromosome aberrations (e.g. Turner's syndrome), polycystic ovaries (PCO), clarifying the causes of amenorrhea, menopausal syndrome, and suspected Leydig cell insufficiency. Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration Please note Reference Range Reviewed w.ef 06/02/24 .

Sample Type : Serum

---------- End Of Report ----------

These tests are accredited under ISO 15189:2012 unless specified by (*)
Sample processed on the same day of receipt unless specified otherwise.
Test results pertains only the sample tested and to be correlated with clinical history.
Reference range related to Age/Gender.

Dr. Solmaz Siddiqui
Laboratory Director
DHA/LS/248469

Patient Sample Collected On : 20-10-2024 14:07:00
Authenticated On : 22-10-2024 20:32:07

Received On : 22-10-2024 19:41:00
Released On : 22-10-2024 20:44:47

Esmeralda Obenita
Lab Incharge
DHA-P-2992011